Dive into the Biopharma Space

Whether you're mapping the antibody development landscape, identifying partnership opportunities, or sourcing leads in immunotherapy,...

In Q1 2025, 26 new and emerging bio/pharma companies were identified, with the majority based in the U.S.—California and Massachusetts leading the count. Most of these companies focus on therapeutics, signaling strong investor interest. Verdiva Bio topped funding with $411M, followed by Kardigan and Windward Bio. Explore geographic trends, sector focus, and top-funded startups in our latest biopharmIQ report.

Whether you’re scouting investment trends, tracking competitors, or preparing reports for market research or investor outreach,...

Whether you're scouting Phase 3 candidates for partnership or identifying innovative early-stage biotech startups, BiopharmIQ’s clinical...

Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics,...

BiopharmIQ is designed to empower sales and marketing professionals in the life sciences industry with targeted lists of companies and...

7 FDA approval decisions are expected by March 2025 with insights from biopharmIQs platform. Learn about them and our new Team Plan.

The global biotech and pharmaceutical landscape in 2024 continued to attract significant investment, with our BiopharmIQ system capturing...

The latest wave of new and emerging biologic companies in 2024 highlights a continued diversity of technology areas with a strong focus...

Bio/pharma continued to attract investments in December 2024 to support the discovery and development of new bio/pharma therapeutics. In...

We've come a long way since the first monoclonal antibody, Muromonab-CD3 (OKT3) was approved in 1986. It took more than 30 years after...

This annual report analyzes our biopharmIQ data on new/emerging bio/pharma companies for 2024 to provide insights into the geographic and...

We used our  biopharmIQ online platform  to identify upcoming FDA approval (PDUFA) dates for biopharma companies through the end of...

We identified two (2) new or newly emerging biotech companies for December 2024. To find these new/emerging bio/pharma companies, every...

We analyzed biotech funding data on our online biopharmIQ platform to identify companies who had early-stage (Angel/Pre-Seed, Seed,...

We’ve identified seven (7) new or newly emerging bio/pharma companies for November 2024. To detect these new/emerging bio/pharma ...

We used our   biopharmIQ online platform  to identify upcoming FDA approval (PDUFA) dates for small and mid-sized biopharma companies...

There is a lot that has been published about the possible impact of AI on healthcare and the development of new therapeutics. In fact,...

November has 4 FDA approvals so far. Most recently, the FDA approved Jazz Pharmaceuticals & Zymeworks’ Ziihera (zanidatamab) and Autolus’...

We analyzed biotech funding data on our online biopharmIQ platform  to identify companies who had late-stage* biotech funding events...